Cargando…

Cancer Stemness: p53 at the Wheel

The tumor suppressor p53 maintains an equilibrium between self-renewal and differentiation to sustain a limited repertoire of stem cells for proper development and maintenance of tissue homeostasis. Inactivation of p53 disrupts this balance and promotes pluripotency and somatic cell reprogramming. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghatak, Dishari, Das Ghosh, Damayanti, Roychoudhury, Susanta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830093/
https://www.ncbi.nlm.nih.gov/pubmed/33505918
http://dx.doi.org/10.3389/fonc.2020.604124
_version_ 1783641327523594240
author Ghatak, Dishari
Das Ghosh, Damayanti
Roychoudhury, Susanta
author_facet Ghatak, Dishari
Das Ghosh, Damayanti
Roychoudhury, Susanta
author_sort Ghatak, Dishari
collection PubMed
description The tumor suppressor p53 maintains an equilibrium between self-renewal and differentiation to sustain a limited repertoire of stem cells for proper development and maintenance of tissue homeostasis. Inactivation of p53 disrupts this balance and promotes pluripotency and somatic cell reprogramming. A few reports in recent years have indicated that prevalent TP53 oncogenic gain-of-function (GOF) mutations further boosts the stemness properties of cancer cells. In this review, we discuss the role of wild type p53 in regulating pluripotency of normal stem cells and various mechanisms that control the balance between self-renewal and differentiation in embryonic and adult stem cells. We also highlight how inactivating and GOF mutations in p53 stimulate stemness in cancer cells. Further, we have explored the various mechanisms of mutant p53-driven cancer stemness, particularly emphasizing on the non-coding RNA mediated epigenetic regulation. We have also analyzed the association of cancer stemness with other crucial gain-of-function properties of mutant p53 such as epithelial to mesenchymal transition phenotypes and chemoresistance to understand how activation of one affects the other. Given the critical role of cancer stem-like cells in tumor maintenance, cancer progression, and therapy resistance of mutant p53 tumors, targeting them might improve therapeutic efficacy in human cancers with TP53 mutations.
format Online
Article
Text
id pubmed-7830093
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78300932021-01-26 Cancer Stemness: p53 at the Wheel Ghatak, Dishari Das Ghosh, Damayanti Roychoudhury, Susanta Front Oncol Oncology The tumor suppressor p53 maintains an equilibrium between self-renewal and differentiation to sustain a limited repertoire of stem cells for proper development and maintenance of tissue homeostasis. Inactivation of p53 disrupts this balance and promotes pluripotency and somatic cell reprogramming. A few reports in recent years have indicated that prevalent TP53 oncogenic gain-of-function (GOF) mutations further boosts the stemness properties of cancer cells. In this review, we discuss the role of wild type p53 in regulating pluripotency of normal stem cells and various mechanisms that control the balance between self-renewal and differentiation in embryonic and adult stem cells. We also highlight how inactivating and GOF mutations in p53 stimulate stemness in cancer cells. Further, we have explored the various mechanisms of mutant p53-driven cancer stemness, particularly emphasizing on the non-coding RNA mediated epigenetic regulation. We have also analyzed the association of cancer stemness with other crucial gain-of-function properties of mutant p53 such as epithelial to mesenchymal transition phenotypes and chemoresistance to understand how activation of one affects the other. Given the critical role of cancer stem-like cells in tumor maintenance, cancer progression, and therapy resistance of mutant p53 tumors, targeting them might improve therapeutic efficacy in human cancers with TP53 mutations. Frontiers Media S.A. 2021-01-11 /pmc/articles/PMC7830093/ /pubmed/33505918 http://dx.doi.org/10.3389/fonc.2020.604124 Text en Copyright © 2021 Ghatak, Das Ghosh and Roychoudhury http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Ghatak, Dishari
Das Ghosh, Damayanti
Roychoudhury, Susanta
Cancer Stemness: p53 at the Wheel
title Cancer Stemness: p53 at the Wheel
title_full Cancer Stemness: p53 at the Wheel
title_fullStr Cancer Stemness: p53 at the Wheel
title_full_unstemmed Cancer Stemness: p53 at the Wheel
title_short Cancer Stemness: p53 at the Wheel
title_sort cancer stemness: p53 at the wheel
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830093/
https://www.ncbi.nlm.nih.gov/pubmed/33505918
http://dx.doi.org/10.3389/fonc.2020.604124
work_keys_str_mv AT ghatakdishari cancerstemnessp53atthewheel
AT dasghoshdamayanti cancerstemnessp53atthewheel
AT roychoudhurysusanta cancerstemnessp53atthewheel